Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Comorbidity of cardiovascular diseases reciprocally aggravates their course and induces the need to use safety and well-tolerated drugs. Pharmacological and pharmacokinetic properties of lercanidipine – the third-generation calcium channel blocker – are characterized by high lipophilicity and tissue selectivity. Clinical studies provide evidence of antihypertensive efficacy and safety of lercanidipine that is successfully used in patients with arterial hypertension and coronary heart disease.

About the Author

E. L. Trisvetova
Belarusian State Medical University
Dzerzhinsky prosp. 83, Minsk, 220116 Republic of Belarus


1. Mendis S., Puska P., Norrving B. (Eds). Global Atlas on Cardiovascular Disease Prevention and Control. Geneva:WHO; 2011.

2. Go A.S., Mozaffarian D., Roger V.L., et al. Heart Disease and Stroke Statistics-2014 Update. Circulation 2014;129:e28-e292.

3. MacMachon S., Alderman M.H., Lindholm L.H. et al. Blood-pressure-related disease is a global health priority. Lancet 2008;371(9623):1480-2.

4. Oganov R.G., Kontsevaya A.V., Kalinina A.M. Economic burden from cardiovascular diseases in the Russian Federation. Cardiovascular Therapy and Prevention 2011; (4):4-9. Russian (Оганов Р.Г., Конце-вая А.В., Калинина А.М. Экономический ущерб от сердечно-сосудистых заболеваний в Российской федерации. Кардиоваскулярная терапия и профилактика 2011;(4):4-9).

5. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA1982;248:1465-77.

6. Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2: Shortterm reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990;335:827-38.

7. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34(28):2159-219.

8. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International VerapamilTrandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290(21):2805-2816.

9. Sidorenko B.A., Preobrazhensky D.V. Calcium channel blockers. Moscow: JSC Informatic 1997. Russian (Сидоренко Б.А., Преображенский Д.В. Антагонисты кальция. М.: АОЗТ Информатик; 1997).

10. Ostroumova O.D., Maksimov M.L., Kopchenov I.I. The third-generation calcium channelblocker lercanidipine: new possibilities in the treatment of hypertension. Ration Pharmacother Cardiol 2013; 9 (1) :79-85. Russian (Остроумова О.Д., Максимов М.Л., Копченов И.И. Антагонист кальция третье-го поколения лерканидипин: новые возможности в лечении артериальной гипертонии. Ра-циональная Фармакотерапия в Кардиологии 2013;9(1):79-85).

11. Lukina Y.V., Martsevich S.Y. Calcium channel blocker lercanidipine position as given by evidence of Cardiology. Ration Pharmacother Cardiol 2010; 6 (4) :558-64. Russain (Лукина Ю.В., Марцевич С.Ю. Позиции антагониста кальция лерканидипина по данным доказательной кардиологии. Ра-циональная Фармакотерапия в Кардиологии 2010;6(4):558-64).

12. Eisenberg M.J., Brox A., Bestawros A.N. Calcium channel blockers: An update. Am J Med 2004;116:35-43.

13. Bang L.M., Chapman T.M., Goa K.L. Lercanidipine: A Reviews of its Efficacy in the Management of Hypertension Drugs 2003;63(22):2449-72.

14. Beckey C., Lundy A., Lutfi N. Lercanidipine in the treatment of hypertension. Annals of Pharmacotherapy 2007;41(3):465-73.

15. Herbette L.G., Vecchiarelli M., Sartani A., Leonardi A. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press Suppl 1998;2:10-7.

16. Burnier M., Pruijm M., Wuerzner G. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine Expert Opin Drug Metab Toxicol 2009;5(8):981-7.

17. Leonetti G., Magnani B., Pessina A.C., et al., on behalf of the Cohort study group. Tolerability of longterm treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002;15:932-40.

18. Fogari R., Malamani G.D., Zoppi A., et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel-group study. Curr Ther Res ClinExp 2000;61:850-62.

19. Messerli F.H. Calcium antagonists in hypertension: from hemodynamics to outcomes. Am J Hypertens 2002;15:94S-97S.

20. Barrios V., Navarro A., Esteras A. et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002;11(2):95-100.

21. Zancetti A., Bond G., Henning M. et al. Emerging data on calcium channel blockers: the COHORT study. ClinCardiol 2003;26(suppl. 2,II): 17-20.

22. Romito R., Pansini M., Francesco P.F., et al. Comparative Effect of Lercanidipine, Felodipine, and Nifedipine GITS on Blood Pressure and Heart Rate in Patients With Mild to Moderate Arterial Hypertension: The Lercanidipine in Adults (LEAD) Study. JCN 2003;4(5):249-53.

23. Makarounas-Kirchmann K., Glover-Koudounas S., Ferrari P. Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther 2010;32(2):401-2.

24. Agrawal R., Marx A., Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as addon to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens 2006;24(1):185-92.

25. McClellan K.J., Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000;60(5):1123-40.

26. Testa R., Leonardi A., Tajana A., et al. Lercanidipine (Rec 15/2375): a novel 1,4–dihydropyridine calcium antagonist for hypertension. Cardiovascular Drug Reviews 1997;15(3):187-219.

27. Cicero A.F.G., Gerocarni B., Rosticci M., Borghi C. Blood Pressure and Metabolic Effect of a Combination of Lercanidipine with Different Antihypertensive Drugs in Clinical Practice. Clinical and Experimental Hypertension 2012;34(2):113-7.

28. Rossoni G., Bernareggi M., De Gennaro Colonna V. et al. Lercanidipine protects the heart from low– flow ischemia damage and antagonizes the vasopressor activity of endothelin–1. J Cardiovascul Pharmacol 1997;29 (suppl.1):S41-S47.

29. Vasigar P., Batmanabane M. Anti-inflammatory activity of calcium channel blocker lercanidipine hydrochloride. J Pharmacology pharmacotherapeutics 2013;4(4):238-42.

30. Martinez M.L., Lopes L.F., Coelho E.B., et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 2006;47(1):117-22.

31. Martinez M.L., Castro M.M., Rizzi E. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol2008;591(1-3):224-230.

32. Farah R., Shurtz-Swirski R. Lercanidipine effect on polymorphonuclear leukocyte-related inflammation and insulin resistance in essential hypertension patients. International J Medicine and Medical Sciences 2013;5(2):35-42.

33. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Rev Esp Cardiol (Engl Ed) 2014;67(2):135.

34. National guidelines for diagnosis and treatment of stable angina. Cardiovascular Therapy and Prevention 2008; 7 (6) suppl 4: 1-56. Russian(Национальные рекомендации по диагностике и лечению ста-бильной стенокардии. Кардиоваскулярная терапия и профилактика 2008; 7(6) Приложение 4: 1-56).

35. Kodama S., Inoue Y., Michara H. et al. Prognostic factors for the long-term survival in patients with vasospastic angina: Analysis of effects of patients’ characteristics and therapeutic drugs. J Cardiol 2009;1(54):10-20.

36. De A., Bala N. N. Current Aspects in the Treatment of Angina Pectoris. In J Research in Pharmaceutical and Biomedical Sciences 2011;2(2):351-9.

37. Wong N. D. Epidemiological studies of CHD and the evolution of preventive cardiologyNature Reviews Cardiology 2014;11:276-89.

38. Morisco C., Trimarco B. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double-blind controlled study. Cardiavasc Pharmacol 1997; 29 (Suppl 2): S26-30.

39. Rengo F., Romis L. Activity of Lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hypertension. J Cardiovasc Pharmacol 1997;29(Suppl2):S54-58.

40. Aranda P., Aranda F.T., Bianchi J.L. et al. Therapeutic efficacy and tolerability of Lercanidipine versus candesartan, alone or in combination, in mild-moderate essential hypertensives. J Hypertens 2000;18(Suppl 2): S152.

41. Acanfora D, Gheorghiade M, Trojano L, et al. A randomized, double-blind comparison of lercanidipine 10 and 20 mg in patients with stable effort angina: clinical evaluation of cardiac function by ambulatory ventricular scintigraphic monitoring. Am J Ther 2004;11(6):423-32.

42. Sasaki T, Maruyama H, Kase Y, et al. Antianginal effects of lercanidipine on the vasopressin or methacholine induced anginal model in rats. Biol Pharm Bull 2005;28(5):811-6.


For citations:


Views: 835

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)